# Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections

> **NCT01893346** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 35 (actual)

## Conditions studied

- Systemic Infections

## Interventions

- **DRUG:** CAZ-AVI

## Key facts

- **NCT ID:** NCT01893346
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01893346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01893346, "Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01893346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*